Analysis of variance of the effect of HR TA-TMA on cost per day and total cost compared with that of SR TA-TMA
| . | Univariate model (n = 137) . | Multivariable model (n = 137) . | ||
|---|---|---|---|---|
| Factor . | P value . | Factors . | P value . | |
| Cost per day | HR-TA-TMA | .002 | HR-TA-TMA | .003 |
| HLA mismatch | .260 | |||
| Infection | .304 | |||
| Grade 3/4 GVHD | .045 | |||
| Total cost | HR-TA-TMA | .001 | HR-TA-TMA | .004 |
| HLA mismatch | .408 | |||
| Infection | .871 | |||
| Grade 3/4 GVHD | <.001 | |||
| . | Univariate model (n = 137) . | Multivariable model (n = 137) . | ||
|---|---|---|---|---|
| Factor . | P value . | Factors . | P value . | |
| Cost per day | HR-TA-TMA | .002 | HR-TA-TMA | .003 |
| HLA mismatch | .260 | |||
| Infection | .304 | |||
| Grade 3/4 GVHD | .045 | |||
| Total cost | HR-TA-TMA | .001 | HR-TA-TMA | .004 |
| HLA mismatch | .408 | |||
| Infection | .871 | |||
| Grade 3/4 GVHD | <.001 | |||
Patients were stratified as having HR TA-TMA if they had sCb-9 level > the upper limit of normal and proteinuria > 2 mg/mg or either elevated sC5b-9 level or proteinuria and multiorgan dysfunction.
The bolded values are statistically significant.